UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM N-PX
ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY
Investment Company Act File number: 811-01528
Bruce Fund, Inc.
(Exact name of registrant as specified in charter)
20 North Wacker Drive, Suite 2414, Chicago, IL 60606
(Address of principal executive offices) (Zip code)
Robert B. Bruce
20 North Wacker Drive, Suite 2414
Chicago, Illinois 60606
(Name and address of agent for service)
Registrant's telephone number, including area code: 312-236-9160
Date of fiscal year end: June 30
Date of reporting period: 07/01/2019 - 06/30/2020
Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (Secs. 239.24 and 274.5 of this chapter),to file reports with the Commission, not later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b 1-4).The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.
A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget C'OMB") control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. Sec. 3507.
Bruce Fund, Inc.
Annual Proxy Report
Report Period: July 1, 2019 to June 30, 2020
Security Name | Ticker | Cusip | Meeting Date | Proposed (M) or (S) | Description | Vote | For, Against or Abstain | For or Against Management |
EDAP | EDAP | 268311107 | 6/30/2020 | M | Agreements | Y | F | F |
EDAP | EDAP | 268311107 | 6/30/2020 | M | Auditors | Y | F | F |
EDAP | EDAP | 268311107 | 6/30/2020 | M | Financials | Y | F | F |
EDAP | EDAP | 268311107 | 6/30/2020 | M | Increase Share Capital | Y | F | F |
EDAP | EDAP | 268311107 | 6/30/2020 | M | Directors | Y | F | F |
EDAP | EDAP | 268311107 | 6/30/2020 | M | Remove Director Ownership | Y | A | A |
EDAP | EDAP | 268311107 | 6/30/2020 | M | Share issuance Others | Y | A | A |
EDAP | EDAP | 268311107 | 6/30/2020 | M | Share issuance Officers | Y | F | F |
Supernus | SUPN | 868459108 | 6/15/2020 | M | Directors | Y | F | F |
Supernus | SUPN | 868459108 | 6/15/2020 | M | Auditors | Y | F | F |
Supernus | SUPN | 868459108 | 6/15/2020 | M | Executive Compensation | Y | F | F |
Supernus | SUPN | 868459108 | 6/15/2020 | M | Incentive Plan | Y | F | F |
Supernus | SUPN | 868459108 | 6/15/2020 | M | Employee Purchase Plan | Y | F | F |
Apple | APPL | 037833100 | 2/26/2020 | M | Directors | Y | F | F |
Apple | APPL | 037833100 | 2/26/2020 | M | Accounting | Y | F | F |
Apple | APPL | 037833100 | 2/26/2020 | M | Executive Compensation | Y | F | F |
Apple | APPL | 037833100 | 2/26/2020 | S | proxy access | Y | A | A |
Apple | APPL | 037833100 | 2/26/2020 | S | Sustainability | Y | A | F |
Apple | APPL | 037833100 | 2/26/2020 | S | Expression | Y | A | F |
Newmont | NEM | 651639106 | 4/21/2020 | M | Directors | Y | F | F |
Newmont | NEM | 651639106 | 4/21/2020 | M | Accounting | Y | F | F |
Newmont | NEM | 651639106 | 4/21/2020 | M | Executive Compensation | Y | F | F |
Newmont | NEM | 651639106 | 4/21/2020 | M | Stock Incentive | Y | F | F |
Mannkind | MNKD | 56400P706 | 5/21/2020 | M | Directors | Y | F | F |
Mannkind | MNKD | 56400P706 | 5/21/2020 | M | Accounting | Y | F | F |
Mannkind | MNKD | 56400P706 | 5/21/2020 | M | Share Authorization | Y | F | F |
Mannkind | MNKD | 56400P706 | 5/21/2020 | M | Incentive plan | Y | F | F |
Mannkind | MNKD | 56400P706 | 5/21/2020 | M | Executive Compensation | Y | F | F |
Fate Theraputics | FATE | 31189P102 | 5/1/2020 | M | Directors | Y | F | F |
Fate Theraputics | FATE | 31189P102 | 5/1/2020 | M | Accounting | Y | F | F |
Fate Theraputics | FATE | 31189P102 | 5/1/2020 | M | Executive Compensation | Y | F | F |
Paratek | PRTK | 699374302 | 6/10/2020 | M | Directors | Y | F | F |
Paratek | PRTK | 699374302 | 6/10/2020 | M | Accounting | Y | F | F |
Paratek | PRTK | 699374302 | 6/10/2020 | M | Executive Compensation | Y | F | F |
Compass Minerals | CMP | 20451N101 | 5/14/2020 | M | Directors | Y | F | F |
Compass Minerals | CMP | 20451N101 | 5/14/2020 | M | Accounting | Y | F | F |
Compass Minerals | CMP | 20451N101 | 5/14/2020 | M | Executive Compensation | Y | F | F |
Compass Minerals | CMP | 20451N101 | 5/14/2020 | M | Incentive plan | Y | F | F |
Merck | MRK | 58933Y105 | 5/26/2020 | M | Directors | Y | F | F |
Merck | MRK | 58933Y105 | 5/26/2020 | M | Compensation | Y | F | F |
Merck | MRK | 58933Y105 | 5/26/2020 | M | Accounting | Y | F | F |
Merck | MRK | 58933Y105 | 5/26/2020 | S | Written consent | Y | A | F |
Merck | MRK | 58933Y105 | 5/26/2020 | S | Allocation tax savings | Y | A | F |
IBM | IBM | 459200101 | 4/28/2020 | M | Directors | Y | A | A |
IBM | IBM | 459200101 | 4/28/2020 | M | Accounting | Y | F | F |
IBM | IBM | 459200101 | 4/28/2020 | M | Executive Compensation | Y | F | F |
IBM | IBM | 459200101 | 4/28/2020 | S | Director Removal | Y | F | A |
IBM | IBM | 459200101 | 4/28/2020 | S | Written consent | Y | A | F |
IBM | IBM | 459200101 | 4/28/2020 | S | Independent Chairman | Y | A | F |
Pfizer | PFE | 717081103 | 4/23/2020 | M | Directors | Y | F | F |
Pfizer | PFE | 717081103 | 4/23/2020 | M | Accounting | Y | F | F |
Pfizer | PFE | 717081103 | 4/23/2020 | M | Executive Compensation | Y | F | F |
Pfizer | PFE | 717081103 | 4/23/2020 | S | Proxy Access | Y | A | F |
Pfizer | PFE | 717081103 | 4/23/2020 | S | Written Consent | Y | A | F |
Pfizer | PFE | 717081103 | 4/23/2020 | S | Lobbying | Y | F | A |
Pfizer | PFE | 717081103 | 4/23/2020 | S | Independent Chair | Y | A | F |
Pfizer | PFE | 717081103 | 4/23/2020 | S | Gender Pay Gap | Y | A | F |
Nextera | NEE | 65339F101 | 5/21/2020 | M | Directors | Y | F | F |
Nextera | NEE | 65339F101 | 5/21/2020 | M | Auditors | Y | F | F |
Nextera | NEE | 65339F101 | 5/21/2020 | M | Compensation | Y | F | F |
Nextera | NEE | 65339F101 | 5/21/2020 | S | Political Contributions | Y | F | A |
Nextera | NEE | 65339F102 | 5/22/2020 | S | Written Consent | N | A | F |
Allstate | ALL | 020002101 | 5/19/2020 | M | Directors | Y | F | F |
Allstate | ALL | 020002101 | 5/19/2020 | M | Auditors | Y | F | F |
Allstate | ALL | 020002101 | 5/19/2020 | M | Compensation | Y | F | F |
Allergan | AGN | G0177J108 | 10/14/2019 | M | Arrangement | Y | F | F |
Allergan | AGN | G0177J108 | 10/14/2019 | M | In Effect | Y | F | F |
Allergan | AGN | G0177J108 | 10/14/2019 | M | Cancel shares | Y | F | F |
Allergan | AGN | G0177J108 | 10/14/2019 | M | New shares | Y | F | F |
Allergan | AGN | G0177J108 | 10/14/2019 | M | Amend Articles | Y | F | F |
Allergan | AGN | G0177J108 | 10/14/2019 | M | Compensation | Y | F | F |
Allergan | AGN | G0177J108 | 10/14/2019 | M | Adjournment | Y | F | F |
Bausch Health | BHC | 071734107 | 4/28/2020 | M | Directors | Y | F | F |
Bausch Health | BHC | 071734107 | 4/28/2020 | M | Compensation | Y | F | F |
Bausch Health | BHC | 071734107 | 4/28/2020 | M | Auditors | Y | F | F |
Bausch Health | BHC | 071734107 | 4/28/2020 | M | Incentive Plan | Y | F | F |
Flotek | FTK | 343389102 | 5/5/2020 | M | Directors | Y | F | F |
Flotek | FTK | 343389102 | 5/5/2020 | M | Increase shares | Y | F | F |
Flotek | FTK | 343389102 | 5/5/2020 | M | Compensation | Y | F | F |
Amerco | UHAL | 023586100 | 8/22/2019 | M | Directors | Y | F | F |
Amerco | UHAL | 023586100 | 8/22/2019 | M | Board decisions | Y | F | F |
Amerco | UHAL | 023586100 | 8/22/2019 | M | Accounting | Y | F | F |
Amerco | UHAL | 023586100 | 8/22/2019 | M | Director election | Y | Abstain | A |
Abbvie | ABBV | 00287Y109 | 5/8/2020 | M | Directors | Y | F | F |
Abbvie | ABBV | 00287Y109 | 5/8/2020 | M | Auditors | Y | F | F |
Abbvie | ABBV | 00287Y109 | 5/8/2020 | M | Say on Pay | Y | F | F |
Abbvie | ABBV | 00287Y109 | 5/8/2020 | M | Supermajority | Y | F | F |
Abbvie | ABBV | 00287Y109 | 5/8/2020 | S | Lobbying | Y | F | A |
Abbvie | ABBV | 00287Y109 | 5/8/2020 | S | Independent Chair | Y | A | F |
Abbvie | ABBV | 00287Y109 | 5/8/2020 | S | Drug Pricing | Y | A | F |
Prothena | PRTA | G72800108 | 5/18/2020 | M | Directors | Y | F | F |
Prothena | PRTA | G72800108 | 5/18/2020 | M | Auditors | Y | F | F |
Prothena | PRTA | G72800108 | 5/18/2020 | M | Compensation | Y | F | F |
Prothena | PRTA | G72800108 | 5/18/2020 | M | Long term Incentive Plan | Y | F | F |
Prothena | PRTA | G72800108 | 5/18/2020 | M | Option Exchange | Y | F | F |
Prothena | PRTA | G72800108 | 5/18/2020 | M | Reserves | Y | F | F |
Abbott | ABT | 002824100 | 4/24/2020 | M | Directors | Y | F | F |
Abbott | ABT | 002824100 | 4/24/2020 | M | Say on Pay | Y | F | F |
Abbott | ABT | 002824100 | 4/24/2020 | M | Accounting | Y | F | F |
Abbott | ABT | 002824100 | 4/24/2020 | S | Lobbying Disclosure | Y | F | A |
Abbott | ABT | 002824100 | 4/24/2020 | S | Metrics Disclosure | Y | A | F |
Abbott | ABT | 002824100 | 4/24/2020 | S | By Law Amendments | Y | A | F |
Abbott | ABT | 002824100 | 4/24/2020 | S | Majority Vote | Y | A | F |
Sirius XM Holding | SIRI | 82968B103 | 6/4/2020 | M | Directors | Y | F | F |
Sirius XM Holding | SIRI | 82968B103 | 6/4/2020 | M | Accounting | Y | F | F |
Sirius XM Holding | SIRI | 82968B103 | 6/4/2020 | M | Compensation | Y | F | F |
Duke Energy | DUK | 26441C204 | 5/7/2020 | M | Directors | Y | F | F |
Duke Energy | DUK | 26441C204 | 5/7/2020 | M | Auditors | Y | F | F |
Duke Energy | DUK | 26441C204 | 5/7/2020 | M | Compensation | Y | F | F |
Duke Energy | DUK | 26441C204 | 5/7/2020 | S | Political contributions | Y | F | A |
Duke Energy | DUK | 26441C204 | 5/7/2020 | S | Independent Chair | Y | A | F |
Duke Energy | DUK | 26441C204 | 5/7/2020 | S | Supermajority | Y | F | N/A |
Duke Energy | DUK | 26441C204 | 5/7/2020 | S | Lobbying Expenses | Y | F | A |
Avista | AVA | 05379B107 | 5/11/2020 | M | Directors | Y | F | F |
Avista | AVA | 05379B107 | 5/11/2020 | M | Auditors | Y | F | F |
Avista | AVA | 05379B107 | 5/11/2020 | M | Compensation | Y | F | F |
Solitario | XPL | 8342EP107 | 6/17/2020 | M | Directors | Y | F | F |
Solitario | XPL | 8342EP107 | 6/17/2020 | M | Auditors | Y | F | F |
Solitario | XPL | 8342EP107 | 6/17/2020 | M | Compensation | Y | F | F |
XCEL Energy | XEL | 98389B100 | 5/22/2020 | M | Directors | Y | F | F |
XCEL Energy | XEL | 98389B100 | 5/22/2020 | M | Auditors | Y | F | F |
XCEL Energy | XEL | 98389B100 | 5/22/2020 | M | Compensation | Y | F | F |
XCEL Energy | XEL | 98389B100 | 5/22/2020 | S | Climate | Y | A | F |
WEC Energy | WEC | 92939U106 | 5/6/2020 | M | Directors | Y | F | F |
WEC Energy | WEC | 92939U106 | 5/6/2020 | M | Auditors | Y | F | F |
WEC Energy | WEC | 92939U106 | 5/6/2020 | M | Compensation | Y | F | F |
General Electric | GE | 369604103 | 5/5/2020 | M | Directors | Y | F | F |
General Electric | GE | 369604103 | 5/5/2020 | M | Auditors | Y | F | F |
General Electric | GE | 369604103 | 5/5/2020 | M | Compensation | Y | F | F |
General Electric | GE | 369604103 | 5/5/2020 | S | Independent Chairman | Y | A | F |
CMS Energy | CMS | 125896100 | 5/1/2020 | M | Directors | Y | F | F |
CMS Energy | CMS | 125896100 | 5/1/2020 | M | Auditors | Y | F | F |
CMS Energy | CMS | 125896100 | 5/1/2020 | M | Compensation | Y | F | F |
CMS Energy | CMS | 125896100 | 5/1/2020 | M | Incentive plan | Y | F | F |
CMS Energy | CMS | 125896100 | 5/1/2020 | S | Political contributions | Y | F | A |
SIGNATURES
Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Bruce Fund, Inc.
By: | /s/ Robert B. Bruce | |
Robert B. Bruce, President | ||
Date: | 8/20/2020 |